<\/p>\n
U.S. Preventive Services Task Force
Update, 2002 Release<\/p>\n
Summary of Recommendations<\/strong><\/p>\n The USPSTF concluded that the harmful effects of estrogen and progestin are Better data on benefits and harms are expected from ongoing randomized Guide to What’s New<\/a> (PDF file<\/a>, 73 Return to Quick Menu: Chemoprevention Hormone Replacement Therapy U.S. Preventive Services Task ForceUpdate, 2002 Release Summary of Recommendations The U.S. Preventive Services Task Force (USPSTF) recommends against the routine use of estrogen and progestin for the prevention of chronic conditions in postmenopausal women. D recommendation.Rationale: The USPSTF found fair to good evidence that the combination of estrogen and….<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1525,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"class_list":["post-1530","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/comments?post=1530"}],"version-history":[{"count":1,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1530\/revisions"}],"predecessor-version":[{"id":1532,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1530\/revisions\/1532"}],"up":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1525"}],"wp:attachment":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/media?parent=1530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n routine use of estrogen and progestin for the prevention of chronic conditions
\n in postmenopausal women.<\/strong> D
\n recommendation<\/a><\/strong>.
Rationale:<\/em> The USPSTF found fair to good
\n evidence that the combination of estrogen and progestin has both benefits and
\n harms. Benefits include increased bone mineral density (good evidence),
\n reduced risk for fracture (fair to good evidence), and reduced risk for
\n colorectal cancer (fair evidence). Harms include increased risk for breast
\n cancer (good evidence), venous thromboembolism (good evidence), coronary heart
\n disease (CHD) (fair to good evidence), stroke (fair evidence), and
\n cholecystitis (fair evidence). Evidence was insufficient to assess the effects
\n of HRT on other important outcomes, such as dementia and cognitive function,
\n ovarian cancer, mortality from breast cancer or cardiovascular disease, or
\n all-cause mortality.<\/p>\n
\n likely to exceed the chronic disease prevention benefits in most women. The
\n USPSTF did not evaluate the use of HRT to treat symptoms of menopause, such as
\n vasomotor symptoms (hot flashes) or urogenital symptoms. The balance of
\n benefits and harms for an individual woman will be influenced by her personal
\n preferences, individual risks for specific chronic diseases, and the presence
\n of menopausal symptoms.<\/p>\n<\/li>\n
\n or against the use of unopposed estrogen for the prevention of chronic
\n conditions in postmenopausal women who have had a hysterectomy.<\/strong> I
\n recommendation<\/a><\/strong>.
Rationale:<\/em> The USPSTF found fair-to-good
\n evidence that the use of unopposed estrogen has both benefits and harms.
\n Although most current data come from observational studies, likely benefits
\n include increased bone mineral density, reduced fracture risk, and reduced
\n risk for colorectal cancer. Likely harms include increased risk for venous
\n thromboembolism, cholecystitis, and stroke; in women who have not had a
\n hysterectomy, unopposed estrogen increases the risk for endometrial cancer.
\n Evidence is insufficient to determine the effects of unopposed estrogen on the
\n risk for breast and ovarian cancer, CHD, dementia and cognitive function, or
\n mortality. As a result, the USPSTF could not determine whether the benefits of
\n unopposed estrogen outweigh the harms for women who have had a hysterectomy.<\/p>\n
\n trials, including the Women’s Health Initiative (WHI) study of unopposed
\n estrogen in women who have had a hysterectomy.3<\/a><\/sup><\/p>\n<\/li>\n<\/ul>\n
\n
\nClinical Preventive Services, 3rd Edition: Periodic Updates<\/em><\/a> (available
\nearly 2003)
Hormone Replacement Therapy, 2002
Recommendations and
\nRationale<\/a> (PDF
\nfile<\/a>, 87 KB)
Summary of the
\nEvidence<\/a> (PDF file<\/a>, 138
\nKB)
Systematic Evidence Reviews
HRT and Breast Cancer
\n(File Download<\/a>,
\n203 KB)
HRT and Cardiovascular Disease (File Download<\/a>,
\n536 KB)
HRT and
\nCognition<\/a> (File
\nDownload<\/a>, 144 KB)
HRT and Osteoporosis (File Download<\/a>, 103
\nKB)
HRT and
\nVenous Thromboembolism<\/a> (File Download<\/a>, 132
\nKB)<\/p>\n
\nKB)
Press
\nRelease<\/a><\/p>\n
\n
\nTopic Index<\/a>
U.S.
\nPreventive Services Task Force (USPSTF)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"